GPR182

Across TCGA pan-cancer cohorts, GPR182 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of GPR182’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GPR182 RNA is repressed in tumor relative to normal tissue. In most cancer types GPR182 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and THCA are the cancer types where GPR182 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GPR182 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	−1.710	<.001	12	view →
KIRP	Female	II,III,IV	−1.620	<.001	11	view →
THCA	Male	III,IV	−1.171	<.001	11	view →
LIHC	Male	II,III,IV	−2.064	<.001	9	view →
UCEC	All	III,IV	−1.203	<.001	8	view →
KICH	Female	All	−1.091	<.001	8	view →
LUSC	Female	All	−0.995	<.001	8	view →
LUAD	Female	III,IV	−0.712	<.001	7	view →
BRCA	Female	II,III,IV	−0.611	<.001	6	view →
COAD	All	II,III,IV	−0.092	<.001	5	view →
CHOL	All	All	−1.102	<.001	2	view →
PRAD	All	All	−0.086	.036	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

GPR182–KIRC

Open the KIRC breakdown →